Akito Hata

5PUBLICATIONS
17CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 16, 2026
Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.

|Jul 11, 2024
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients.

Akito Hata, Shunichiro Iwasawa, Yusuke Sasaki

|Jan 10, 2024
Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor-mutant non-small cell lung cancer.

Akito Hata, Simon Fifer, Kazuo Hasegawa

|Nov 10, 2023
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.

Takehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama

|Nov 18, 2021
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.

Akito Hata, Isamu Okamoto, Naoki Inui

Pageof 1

Frequent Collaborators

1 joint publications

Isamu Okamoto

1 joint publications

Naoki Inui

1 joint publications

Masahiro Morise

1 joint publications

Masayuki Takeda